Drug delivery articles within Nature Reviews Cardiology

Featured

  • Research Highlight |

    In the multicentre, randomized, placebo-controlled RAPID trial, use of symptom-prompted, self-administered, intranasally delivered etripamil was safe and superior to placebo for the conversion of paroxysmal superventricular tachycardia to sinus rhythm.

    • Karina Huynh

  • News & Views |

    Nanotherapies are emerging rapidly as options to treat cardiovascular disease. However, insufficient and heterogeneous delivery remain critical issues. Novel strategies to boost targeted delivery of systemically administered nanoparticles by optimizing the particle physical properties or using immune cells as carriers promise to increase nanotherapeutic effectiveness in cardiovascular and other inflammatory diseases.

    • Bryan Ronain Smith

  • Research Highlight |

    PCSK9 inhibitors are a class of cholesterol-lowering drugs that regulate LDL-receptor degradation. Three new studies show successful reduction of PCSK9 levels by different approaches that all resulted in the lowering of LDL-cholesterol levels.

    • Andrew Robson

  • News & Views |

    Valve replacement is currently the only treatment for calcific aortic valve disease. Studies of an uncommon, genetic form of aortic valve disease have yielded in vitro and mouse models of the disease and a transcriptomic disease signature. Machine learning-driven screens for compounds that normalize this signature promise to enable medical management of aortic valve disease.

    • Suya Wang
    •  & William T. Pu

  • Review Article |

    For therapeutic materials to be delivered to the heart, several barriers need to be overcome. In this Review, Ishikawa and colleagues discuss strategies for targeted delivery of therapeutic materials to the heart, including the use of adeno-associated viruses and exosomes, with a focus on agents directed at modifying gene expression.

    • Susmita Sahoo
    • , Taro Kariya
    •  & Kiyotake Ishikawa

  • Research Highlight |

    A new biomimetic drug delivery system consisting of nanoparticles that are coated with macrophage membrane and responsive to reactive oxygen species enables targeted pharmacotherapy for atherosclerosis in mice while also suppressing local inflammation by sequestering inflammatory factors.

    • Irene Fernández-Ruiz

  • Review Article |

    Lysine acetyltransferases (KATs) and lysine deacetylases (KDACs) are involved in the regulation of lysine acetylation, a conserved post-translational protein modification that is an important modulator of cardiac metabolism. Li and colleagues describe the complex roles of KATs and KDACs in both the normal and diseased heart and provide an overview of the evidence indicating a therapeutic role of KDAC inhibitors in cardiovascular disease.

    • Peng Li
    • , Junbo Ge
    •  & Hua Li

  • Review Article |

    Over the past 20 years, new insights into cardiovascular immunopathology have shifted the therapeutic focus from lipids to inflammation. In this Review, Duivenvoorden and colleagues discuss recent discoveries in the immunopathology of atherosclerosis, advances in bioengineering techniques, and how these advances have guided the development of innovative nanoimmunotherapeutic strategies to modulate immune responses in cardiovascular disease.

    • Raphaël Duivenvoorden
    • , Max L. Senders
    •  & Willem J. M. Mulder

  • Review Article |

    Stent thrombosis is a rare, but serious, complication of percutaneous coronary intervention and is associated with severe morbidity and mortality. In this Review, Ong and Jang discuss the use of intravascular imaging to study stent underexpansion, malapposition, uncovered struts, and neoatherosclerosis as risk factors for stent thrombosis. They also discuss the potential utility of intravascular imaging in the optimization of stent deployment and treatment of stent thrombosis events.

    • Daniel S. Ong
    •  & Ik-Kyung Jang

Browse broader subjects

Browse Drug delivery across other nature.com journals